Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 2/2014

01-02-2014 | Research Article

Association of polymorphisms in interleukin-18 and interleukin-28B genes with outcomes of hepatitis B virus infections: a meta-analysis

Authors: Pu Xia, Mo Zhou, Dao Song Dong, Ya-Nan Xing, Yang Bai

Published in: Tumor Biology | Issue 2/2014

Login to get access

Abstract

Several polymorphisms in the interleukin-18 (IL-18) and nterleukin-28B (IL-28B) genes have been reported to influence hepatitis B virus (HBV) infection. However, the published findings have been conflicting. We conducted meta-analyses of randomized, controlled trials to address the association of IL-18 or IL-28B polymorphisms and the outcomes of HBV infection. Weipu, Wanfang, CNKI, MEDLINE, PubMed, EMBASE, and Cochrane Library databases were employed to search for citations using the MeSH terms as “interleukin-18”/“interleukin-28B” AND “HBV” AND “gene” AND “polymorphism” without any restriction in language and publication year. Meta-analysis was conducted by RevMan 5.0 software. The results showed that the IL28B rs8099917 AA genotype (AA vs AC + CC: odds ratio (OR) = 0.63, 95 % confidence interval (CI) = 0.46–0.87) was associated with a decreased risk of hepatocellular carcinoma (HCC). Carriage of IL28B rs12979860 CC genotype was associated with an increased risk for developing liver cirrhosis among patients with HBV infection (CC vs CT + TT: OR = 1.39, 95 % CI = 1.04–1.85). Further well-designed large studies are warranted to confirm the mechanisms by which these are involved in these outcomes of HBV infection.
Literature
1.
2.
3.
Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol. 2000;15:E3–6.PubMedCrossRef
4.
5.
Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Sem Liver Dis. 1991;11:84–92.CrossRef
6.
Lavanchy D. Hepatitis B, virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107.PubMedCrossRef
7.
McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49:S45–55.PubMedCrossRef
8.
Liu YZ, Hou FQ, Ding P, Ren YY, Li SH, Wang GQ. Pegylated interferon α enhances recovery of memory T cells in e antigen positive chronic hepatitis B patients. Virol J. 2012;9:274.PubMedCentralPubMedCrossRef
9.
Chen L, Liu WQ, Lei JH, Guan F, Li MJ, Song WJ, et al. Chronic Schistosoma japonicum infection reduces immune response to vaccine against hepatitis B in mice. PLoS One. 2012;7:e51512.PubMedCentralPubMedCrossRef
10.
Ben-Ari Z, Mor E, Papo O, Kfir B, Sulkes J, Tambur AR, et al. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol. 2003;98:144–50.PubMedCrossRef
11.
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.PubMedCrossRef
12.
13.
Li W, Jiang Y, Jin Q, Shi X, Jin J, Gao Y, et al. Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. Liver Int. 2011;31:1118–26.PubMedCrossRef
14.
Peng LJ, Guo JS, Zhang Z, Shi H, Wang J, Wang JY. IL28B rs12979860 polymorphism does not influence outcomes of hepatitis B virus infection. Tissue Antigens. 2012;79:302–5.PubMedCrossRef
15.
Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol. 2002;76:10702–7.PubMedCentralPubMedCrossRef
16.
Tanaka-Kataoka M, Kunikata T, Takayama S, Iwaki K, Ohashi K, Ikeda M, et al. In vivo antiviral effect of interleukin 18 in a mouse model of vaccinia virus infection. Cytokine. 1999;11:593–9.PubMedCrossRef
17.
Sun Y, Chen HY, Xin SJ. Effect of IL-18 on peripheral blood mononuclear cells of chronic hepatitis B and hepatitis B virus DNA released by HepG2.2.15 cell lines. Hepatobiliary Pancreat Dis Int. 2004;3:230–4.PubMed
18.
Kim YS, Cheong JY, Cho SW, Lee KM, Hwang JC, Oh B, et al. A functional SNP of the Interleukin-18 gene is associated with the presence of hepatocellular carcinoma in hepatitis B virus-infected patients. Dig Dis Sci. 2009;54:2722–8.PubMedCrossRef
19.
Higa S, Hirano T, Mayumi M, Hiraoka M, Ohshima Y, Nambu M, et al. Association between interleukin-18 gene polymorphism 105A/C and asthma. Clin Exp Allergy. 2003;33:1097–102.PubMedCrossRef
20.
Giedraitis V, He B, Huang WX, Hillert J. Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol. 2001;112:146–52.PubMedCrossRef
21.
Khripko OP, Sennikova NS, Lopatnikova JA, Khripko JI, Filipenko ML, Khrapov EA, et al. Association of single nucleotide polymorphisms in the IL-18 gene with production of IL-18 protein by mononuclear cells from healthy donors. Mediators Inflamm. 2008;309721.
22.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.PubMedCrossRef
23.
Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28:123–37.PubMedCrossRef
24.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalyses. BMJ. 2003;327:557–60.PubMedCrossRef
25.
Pereira TV, Rudnicki M, Cheung BM, Baum L, Yamada Y, Oliveira PS, et al. Three endothelial nitric oxide (NOS3) gene polymorphisms in hypertensive and normotensive individuals: meta-analysis of 53 studies reveals evidence of publication bias. J Hypertens. 2007;25:1763–74.PubMedCrossRef
26.
Hirankarn N, Manonom C, Tangkijvanich P, Poovorawan Y. Association of interleukin-18 gene polymorphism (–607A/A genotype) with susceptibility to chronic hepatitis B virus infection. Tissue Antigens. 2007;70:160–3.PubMedCrossRef
27.
Cheong JY, Cho SW, Oh B, Kimm K, Lee KM, Shin SJ, et al. Association of interleukin-18 gene polymorphisms with hepatitis B virus clearance. Dig Dis Sci. 2010;55:1113–9.PubMedCrossRef
28.
Zhang PA, Wu JM, Li Y, Yang XS. Association of polymorphisms of interleukin-18 gene promoter region with chronic hepatitis B in Chinese Han population. World J Gastroenterol. 2005;11:1594–8.PubMed
29.
Migita K, Sawakami-Kobayashi K, Maeda Y, Nakao K, Kondoh S, Sugiura M, et al. Interleukin-18 promoter polymorphisms and the disease progression of hepatitis B virus-related liver disease. Transl Res. 2009;153:91–6.PubMedCrossRef
30.
Chen Q, Liao WJ, He SQ, Yuan SG, Qin LL, Yu YQ, et al. The correlation between single nucleotide polymorphism of interleukin-18 gene promoter and genetic susceptibility to hepatocellular carcinoma. Immunol J. 2012;28:1051–5 [Article in Chinese].
31.
Li N, Gao YF, Zhang TC, Chen P, Li X, Su F. Relationship between interleukin 18 polymorphisms and susceptibility to chronic hepatitis B virus infection. World J Hepatol. 2012;4:105–9.PubMedCentralPubMedCrossRef
32.
Gao JM, Zou YL, Dong H, Tang H, Xu Y, Yan XM. Relationship between HBV infection and polymorphism of IL-18 promoter gene among three minority populations in Yunnan province. Chin J Clin. 2010;4:1525–31 [Article in Chinese].
33.
Chen J, Wang L, Li Y, Cai B, Fu Y, Liao Y, et al. Association analysis between SNPs in IL-28B gene and the progress of hepatitis B infection in Han Chinese. PLoS One. 2012;7(12):e50787.PubMedCentralPubMedCrossRef
34.
Ren S, Lu J, Du X, Huang Y, Ma L, Huo H, et al. Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma. Cancer Immunol Immunother. 2012;61:1433–9.PubMedCrossRef
35.
Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, Hoots WK, et al. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis. 2010;202:1749–53.PubMedCrossRef
36.
Martín-Carbonero L, Rallón NI, Benito JM, Poveda E, González-Lahoz J, Soriano V. Does interleukin-28B single nucleotide polymorphisms influence the natural history of hepatitis B? AIDS Res Hum Retroviruses. 2012;28:1262–4.PubMedCrossRef
37.
Wang Y, Zhang HH, Chen YH, Xie XW, Liao WJ, Qin LL, et al. Correlation between interleukin-28B genetic polymorphisms and primary hepatocellular carcinoma. Zhonghua Yu Fang Yi Xue Za Zhi. 2012;46:527–32 [Article in Chinese].PubMed
38.
Jiao XL, Gao YT, Jing L, Liu T, Shi WX, Guo H, et al. Studies on the relationship between polymorphism of IL-28B rs8099917 and the outcome of HBV infection. Zhonghua Liu Xing Bing Xue Za Zhi. 2011;32:1143–7 [Article in Chinese].PubMed
39.
Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Bignulin S, et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol. 2011;54:716–22.PubMedCrossRef
40.
Dunford L, Carr MJ, Dean J, Nguyen LT, Ta Thi TH, Nguyen BT, et al. A multicentre molecular analysis of hepatitis B and blood-borne virus coinfections in Viet Nam. PLoS One. 2012;7:e39027.PubMedCentralPubMedCrossRef
41.
Holmes JA, Nguyen T, Ratnam D, Heerasing NM, Tehan JV, Bonanzinga S, et al. IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α. J Gastroenterol Hepatol. 2013;28:861–6.PubMedCrossRef
42.
Lee IC, Lin CH, Huang YH, Huo TI, Su CW, Hou MC, et al. IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B. PLoS One. 2013;8:e58071.PubMedCentralPubMedCrossRef
43.
Sonneveld MJ, Wong VW, Wotman AM, Wong GLH, Buster EHCJ, Hansen BE, et al. Polymorphisms at rs12979860 and rs12980275 near IL28B predict serological response to (Peg)-interferon in HBeAg-positive chronic hepatitis B. J Hepatol. 2011;54:S32.CrossRef
Metadata
Title
Association of polymorphisms in interleukin-18 and interleukin-28B genes with outcomes of hepatitis B virus infections: a meta-analysis
Authors
Pu Xia
Mo Zhou
Dao Song Dong
Ya-Nan Xing
Yang Bai
Publication date
01-02-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1151-y

Other articles of this Issue 2/2014

Tumor Biology 2/2014 Go to the issue

Research Article

Association of COX2 gene hypomethylation with intestinal type gastric cancer in samples of patients from northern Brazil

Research Article

FASLG T844C polymorphism and susceptibility to breast cancer: a meta-analysis

Research Article

Effect of the cytokine levels in serum on osteosarcoma

Research Article

Quantitative assessment of the association between XPC Lys939Gln polymorphism and cutaneous melanoma risk

Research Article

Association between Cyclin D1 polymorphism and oral cancer susceptibility: a meta-analysis

Research Article

Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits